Approval · Notice of Compliance 16391 · 2014
RETISOL-A: Notice of Compliance 16391
Issued November 27, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16391
- Date
- November 27, 2014
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Additon of certified product information document
- Therapeutic class
- Topical acne therapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RETISOL-A | Not yet assigned | — |
Medicinal ingredients
- AVOBENZONE 20 MG per G
- OCTINOXATE 75 MG per G
- TRETINOIN 0.105 MG per G
- TRETINOIN 0.26 MG per G
- TRETINOIN 0.53 MG per G
- TRETINOIN 1.05 MG per G